company background image
AGLE

Aeglea BioTherapeutics NasdaqGM:AGLE Stock Report

Last Price

US$0.52

Market Cap

US$31.8m

7D

12.5%

1Y

-92.4%

Updated

17 Aug, 2022

Data

Company Financials +
AGLE fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

AGLE Stock Overview

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases.

Aeglea BioTherapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Aeglea BioTherapeutics
Historical stock prices
Current Share PriceUS$0.52
52 Week HighUS$8.50
52 Week LowUS$0.37
Beta1.77
1 Month Change12.84%
3 Month Change-65.55%
1 Year Change-92.41%
3 Year Change-93.63%
5 Year Change-83.00%
Change since IPO-95.66%

Recent News & Updates

Aug 04

Aeglea BioTherapeutics GAAP EPS of -$0.27 beats by $0.04, revenue of $0.63M misses by $0.08M

Aeglea BioTherapeutics press release (NASDAQ:AGLE): Q2 GAAP EPS of -$0.27 (vs. -0.10 Y/Y)  beats by $0.04. Revenue of $0.63M (-95.4% Y/Y) misses by $0.08M. Shares +5.07% PM.

Jun 09
Can Aeglea BioTherapeutics (NASDAQ:AGLE) Afford To Invest In Growth?

Can Aeglea BioTherapeutics (NASDAQ:AGLE) Afford To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Shareholder Returns

AGLEUS BiotechsUS Market
7D12.5%-2.0%1.1%
1Y-92.4%-23.0%-9.0%

Return vs Industry: AGLE underperformed the US Biotechs industry which returned -22.2% over the past year.

Return vs Market: AGLE underperformed the US Market which returned -8.9% over the past year.

Price Volatility

Is AGLE's price volatile compared to industry and market?
AGLE volatility
AGLE Average Weekly Movement19.2%
Biotechs Industry Average Movement12.3%
Market Average Movement7.6%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.1%

Stable Share Price: AGLE is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 19% a week.

Volatility Over Time: AGLE's weekly volatility has increased from 14% to 19% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201392Anthony Quinnhttps://www.aeglea.com

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company’s lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria.

Aeglea BioTherapeutics Fundamentals Summary

How do Aeglea BioTherapeutics's earnings and revenue compare to its market cap?
AGLE fundamental statistics
Market CapUS$31.82m
Earnings (TTM)-US$87.51m
Revenue (TTM)US$7.03m

4.5x

P/S Ratio

-0.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AGLE income statement (TTM)
RevenueUS$7.03m
Cost of RevenueUS$63.95m
Gross Profit-US$56.92m
Other ExpensesUS$30.59m
Earnings-US$87.51m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.43
Gross Margin-809.64%
Net Profit Margin-1,244.84%
Debt/Equity Ratio0%

How did AGLE perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is AGLE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AGLE?

Other financial metrics that can be useful for relative valuation.

AGLE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Sales Ratio vs Peers

How does AGLE's PS Ratio compare to its peers?

AGLE PS Ratio vs Peers
The above table shows the PS ratio for AGLE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average35.3x
THER Theralink Technologies
80xn/aUS$24.6m
AIMD Ainos
42.5xn/aUS$47.3m
HGEN Humanigen
8.7x69.6%US$35.9m
MRKR Marker Therapeutics
9.9x68.7%US$29.6m
AGLE Aeglea BioTherapeutics
4.5x-91.3%US$31.8m

Price-To-Sales vs Peers: AGLE is good value based on its Price-To-Sales Ratio (4.5x) compared to the peer average (35.3x).


Price to Earnings Ratio vs Industry

How does AGLE's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Sales vs Industry: AGLE is good value based on its Price-To-Sales Ratio (4.5x) compared to the US Biotechs industry average (16.9x)


Price to Sales Ratio vs Fair Ratio

What is AGLE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AGLE PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.5x
Fair PS Ratio0.00002x

Price-To-Sales vs Fair Ratio: AGLE is expensive based on its Price-To-Sales Ratio (4.5x) compared to the estimated Fair Price-To-Sales Ratio (0x).


Share Price vs Fair Value

What is the Fair Price of AGLE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate AGLE's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AGLE's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Aeglea BioTherapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-1.2%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AGLE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AGLE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AGLE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AGLE's revenue is expected to decline over the next 3 years (-91.3% per year).

High Growth Revenue: AGLE's revenue is forecast to decline over the next 3 years (-91.3% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AGLE's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Aeglea BioTherapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-20.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: AGLE is currently unprofitable.

Growing Profit Margin: AGLE is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AGLE is unprofitable, and losses have increased over the past 5 years at a rate of 20.3% per year.

Accelerating Growth: Unable to compare AGLE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AGLE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).


Return on Equity

High ROE: AGLE has a negative Return on Equity (-103.99%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Aeglea BioTherapeutics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: AGLE's short term assets ($96.6M) exceed its short term liabilities ($15.9M).

Long Term Liabilities: AGLE's short term assets ($96.6M) exceed its long term liabilities ($6.7M).


Debt to Equity History and Analysis

Debt Level: AGLE is debt free.

Reducing Debt: AGLE has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AGLE has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: AGLE has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 23.7% each year.


Discover healthy companies

Dividend

What is Aeglea BioTherapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate AGLE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AGLE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AGLE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AGLE's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as AGLE has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.0yrs

Average management tenure


CEO

Anthony Quinn (60 yo)

5.08yrs

Tenure

US$2,623,186

Compensation

Dr. Anthony G. Quinn, M.B. Ch B., PhD., MD, FRCP, has been Member of Scientific Advisory Board at Anokion SA. Dr. Quinn has been President and Chief Executive Officer of Aeglea BioTherapeutics, Inc. since...


CEO Compensation Analysis

Compensation vs Market: Anthony's total compensation ($USD2.62M) is above average for companies of similar size in the US market ($USD753.27K).

Compensation vs Earnings: Anthony's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: AGLE's management team is considered experienced (2 years average tenure).


Board Members

Experienced Board: AGLE's board of directors are considered experienced (5.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: AGLE insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 24.7%.


Top Shareholders

Company Information

Aeglea BioTherapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Aeglea BioTherapeutics, Inc.
  • Ticker: AGLE
  • Exchange: NasdaqGM
  • Founded: 2013
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$31.822m
  • Shares outstanding: 61.17m
  • Website: https://www.aeglea.com

Number of Employees


Location

  • Aeglea BioTherapeutics, Inc.
  • 805 Las Cimas Parkway
  • Suite 100
  • Austin
  • Texas
  • 78746
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/17 00:00
End of Day Share Price2022/08/17 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.